The specificities of four assays for hepatitis C virus (HCV) were compared by using units from volunteer blood donors. Upon Food and Drug Administration licensure of the first immunoassay for anti-HCV, EIA-1, units previously deemed acceptable for transfusion and all subsequent blood donations were screened. EIA-1 repeat-reactive (RR) units were tested for HCV by a second-generation enzyme-linked immunoassay (EIA-2) and by a four-antigen recombinant immunoblot assay (RIBA II) and for HCV RNA by reverse transcriptase polymerase chain reaction. All HCV RNA-positive samples were reactive by both RIBA II and EIA-2. All RIBA TI-reactive sera were EIA-2 RR. In EIA-1, 0.45% of the prescreened units and 0.59%o of the prospectively screened donors were RR. Of these, 52.5 and 54%, respectively, were EIA-2 RR, 71.4 The flavivirus-like entity hepatitis C virus (HCV) is the principal etiological agent of parenterally transmitted non-A, non-B hepatitis (6). The first anti-HCV enzyme immunoassay (EIA-1) established HCV as the major cause of transfusion-associated and community-acquired non-A, non-B hepatitis (10). EIA-1 measures antibodies that bind to a superoxide dismutase fusion protein containing a polypeptide that spans the distal nonstructural domain 3 to the proximal nonstructural domain 4 of the putative viral polyprotein.
IT reactive or HCV RNA positive. In conclusion, RIBA TI and RT PCR results are highly concordant. A sample/cutoff ratio of >5 in EIA-2 is a good discriminator for the likelihood of a true HCV infection on the basis of RT PCR and RIBA II assays.
The flavivirus-like entity hepatitis C virus (HCV) is the principal etiological agent of parenterally transmitted non-A, non-B hepatitis (6) . The first anti-HCV enzyme immunoassay (EIA-1) established HCV as the major cause of transfusion-associated and community-acquired non-A, non-B hepatitis (10) . EIA-1 measures antibodies that bind to a superoxide dismutase fusion protein containing ciOO- 3, a polypeptide that spans the distal nonstructural domain 3 to the proximal nonstructural domain 4 of the putative viral polyprotein.
On 2 May 1990, the anti-HCV EIA-1 was licensed by the U.S. Food and Drug Administration for screening samples from blood and plasma donors in an effort to reduce the incidence of transfusion-associated hepatitis. Subsequently, a second-generation enzyme immunoassay (EIA-2) and a recombinant immunoblot assay (RIBA II) that detected antibodies to a putative core protein (c22) and another part of the NS3 region (c33c) were developed (11) . Since the 5' untranslated region of the HCV genome is conserved, nested reverse transcriptase polymerase chain reaction (RT PCR) amplification of this region allows confirmation of viremia.
EIA-1 and EIA-2 detect antibodies to both superoxide dismutase and HCV-related epitopes. Hence, supplemental assays such as RIBA TT and RT PCR may be needed to confirm HCV infection (1, 7, 11 Only 171 (0.59%) were EIA-2 RR. Of these, only 24 (14%) were confirmed with RIBA II; however, in each instance, the S/C ratio was greater than 5. Thus, even when sera are EIA-1 nonreactive, the S/C ratio in EIA-2 is a good predictor of reactivity in supplemental assays.
DISCUSSION
The isolation and cloning of the HCV genome led to the development of first-generation and then second-generation assays for antibodies to various putative virus-related epitopes. EIA-1 identified 0.3 to 3% of volunteer blood donors as RR for antibodies either to the clOO-3 epitope of HCV or to yeast superoxide dismutase. In the United States, the overall prevalence of EIA-1 RR blood donors is approximately 0.6% (2) . In the first part of our investigation, 0.45% of volunteer blood donor units that had been made available for blood transfusion were RR for anti-HCV in EIA-1. Because the anti-HCV immunoassay also detects antibodies to superoxide dismutase, not all anti-HCV EIA-1 RR units are potentially infectious (8, 13) . In the volunteer blood donor setting, less than 60% of EIA-1 RR samples have been confirmed with supplemental testing (1, 7 (12) .
The S/C ratio on EIA-2 is a good predictor of reactivity on supplemental assays, even when the EIA-1 result is nonreactive. In situations such as organ donation, in which time to perform supplemental assays is limited before a decision is made on whether to use an organ, the S/C ratio may be a useful discriminator of a true-or false-positive anti-HCV EIA-2 result.
In summary, EIA-2 increases the sensitivity and the specificity of anti-HCV detection among volunteer blood donors. Furthermore, a high S/C ratio in EIA-2 is a useful indicator of potential HCV infectivity, on the basis of the correlation with reactive results of the RIBA II and RT PCR assays.
